Collegium Pharmaceutical, Inc. (NASDAQ: COLL) revealed it has been issued an intention of grant letter by the European
Patent Office covering Xtampza (oxycodone) extended-release (ER) capsules.
The specialty pharmaceutical company focused on developing and commercializing innovative abuse-deterrent treatments for chronic
pain and other diseases said that Xtampza ER is its first product using the DETERx technology platform. The company indicated that
it has eight patents that are listed in the FDA Orange Book in the United State currently apart from issued patents in Canada,
Japan and Australia.
Collegium's Chairman and CEO, Michael Heffernan, said, "This patent application is part of Collegium's expanding patent
portfolio covering Xtampza ER and the DETERx technology platform. Building an international patent portfolio is an important part
of our growth strategy outside of the U.S. We continue to evaluate business development opportunities for our product portfolio in
key international markets such as Canada, Japan, Australia, and Europe, amongst others."
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.